Suppr超能文献

如何评估光化性角化病干预措施的疗效?一项聚焦长期结果的综述

How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results.

作者信息

Steeb Theresa, Wessely Anja, Petzold Anne, Schmitz Lutz, Dirschka Thomas, Berking Carola, Heppt Markus V

机构信息

Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany.

出版信息

J Clin Med. 2021 Oct 15;10(20):4736. doi: 10.3390/jcm10204736.

Abstract

Actinic keratoses (AK) are common lesions of the skin caused by cumulative sun exposure. Since AK may progress to invasive cutaneous squamous cell carcinoma (cSCC), guidelines uniformly recommend early and consequent treatment. A variety of interventions are available; however, most randomized controlled trials, meta-analyses, and guidelines focus on outcomes that are usually evaluated 8-12 weeks after the end of treatment. Importantly, these assessments can capture the short-term, transient outcomes, but do not allow any conclusions about long-term results to be drawn and do not reflect the probability of transition towards cSCC. Until now, few studies have assessed the long-term results of interventions for AK. Indeed, finding the most appropriate end-point and adjunct time point for determining the long-term results of interventions for AK remains a challenge. Here, we provide an overview of the different ways of measuring the efficacy of AK treatments, such as using recurrence rates or sustained clearance rates, and discuss methodological aspects. Furthermore, we highlight the importance of evidence from post-marketing surveillance trials for the detection of efficacy values and safety signals. Additionally, we emphasize that a follow-up period of 12 months might not be sufficient to reflect the long-term results and stress the urgent need for a longer follow-up period and regular risk-stratified surveillance.

摘要

光化性角化病(AK)是因长期日晒引起的常见皮肤病变。由于AK可能进展为侵袭性皮肤鳞状细胞癌(cSCC),指南一致推荐早期并持续进行治疗。有多种干预措施可供选择;然而,大多数随机对照试验、荟萃分析和指南关注的结果通常是在治疗结束后8 - 12周进行评估。重要的是,这些评估能够捕捉短期、短暂的结果,但无法得出关于长期结果的任何结论,也不能反映向cSCC转变的可能性。到目前为止,很少有研究评估AK干预措施的长期结果。事实上,找到最适合确定AK干预措施长期结果的终点和辅助时间点仍然是一项挑战。在此,我们概述了测量AK治疗效果的不同方法,例如使用复发率或持续清除率,并讨论方法学方面的问题。此外,我们强调上市后监测试验证据对于检测疗效值和安全信号的重要性。此外,我们强调12个月的随访期可能不足以反映长期结果,并强调迫切需要更长的随访期和定期的风险分层监测。

相似文献

2
A feasibility study of microwave therapy for precancerous actinic keratosis.
Br J Dermatol. 2020 Aug;183(2):222-230. doi: 10.1111/bjd.18935. Epub 2020 Mar 23.
3
Comparison of facial predilection sites for cutaneous squamous cell carcinoma and actinic keratosis in Japanese patients.
J Dermatol. 2014 Dec;41(12):1102-5. doi: 10.1111/1346-8138.12679. Epub 2014 Nov 11.
4
5
Core Outcome Set for Actinic Keratosis Clinical Trials.
JAMA Dermatol. 2020 Mar 1;156(3):326-333. doi: 10.1001/jamadermatol.2019.4212.
6
[Actinic keratosis].
Hautarzt. 2020 Aug;71(8):588-596. doi: 10.1007/s00105-020-04612-4.
8
Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin.
Dermatol Pract Concept. 2024 Sep 1;14(3 S1):e2024146S. doi: 10.5826/dpc.1403S1a146S.
9
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
Safety of topical interventions for the treatment of actinic keratosis.
Expert Opin Drug Saf. 2021 Jul;20(7):801-814. doi: 10.1080/14740338.2021.1915280. Epub 2021 Apr 27.

本文引用的文献

2
Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?
Curr Oncol. 2021 Jun 23;28(4):2317-2325. doi: 10.3390/curroncol28040213.
3
Topical 5% Imiquimod Sequential to Surgery for HPV-Related Squamous Cell Carcinoma of the Lip.
Medicina (Kaunas). 2021 Jun 2;57(6):563. doi: 10.3390/medicina57060563.
4
Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features.
Ital J Dermatol Venerol. 2021 Apr;156(2):213-219. doi: 10.23736/S2784-8671.21.06892-9.
5
Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials.
J Am Acad Dermatol. 2022 May;86(5):1116-1119. doi: 10.1016/j.jaad.2021.04.017. Epub 2021 Apr 16.
6
Safety of topical interventions for the treatment of actinic keratosis.
Expert Opin Drug Saf. 2021 Jul;20(7):801-814. doi: 10.1080/14740338.2021.1915280. Epub 2021 Apr 27.
7
Guidelines of care for the management of actinic keratosis.
J Am Acad Dermatol. 2021 Oct;85(4):e209-e233. doi: 10.1016/j.jaad.2021.02.082. Epub 2021 Apr 2.
8
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.
10
The High Prevalence of Skin Diseases in Adults Aged 70 and Older.
J Am Geriatr Soc. 2020 Nov;68(11):2565-2571. doi: 10.1111/jgs.16706. Epub 2020 Aug 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验